focus -WSS

focus

author：explore 2025-09-27 12:22:15 - browse：7

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Wegovy leads to weight loss. Can it treat depression, too?

explore

WSS

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Kaiser Permanente unions announce official strike date

Pancreatic cancer early detection could be helped by AI

New clues to why women have higher risk of autoimmune disorders

New clues to why women have higher risk of autoimmune disorders

Did you have Obamacare on your GOP debate bingo card?

hotspot

focus

hotspot

Continuity nursing helped my family in our darkest PICU moments

Merck, Johnson & Johnson CEOs will testify on high drug prices

DIEP, the 'gold standard' of breast reconstruction, is under threat

How the Dana

Trump demands the U.S. pay no more for drugs than other countries … again

Pancreatic cancer early detection could be helped by AI

Drug repurposing or repositioning? The language matters

Paxlovid should be available without a positive Covid test

Guidelines to prevent youth baseball injuries need more muscle

Biogen walks away from Aduhelm, years after polarizing approval

knowledge

New clues to why women have higher risk of autoimmune disorders

Senator probes 340B programs at Cleveland Clinic, Bon Secours

WHO recommends dropping component of many flu vaccines

Shingles, which affected Dianne Feinstein, is on the rise

Philips to halt sales of sleep apnea machines in U.S.

How one patient went off dialysis — and others can too

explore

leisure time

entertainment

hotspot